Newsletters

newsletters

Weekly Mass Torts Bulletin 2023-June-5

Opvee, the first nalmefene hydrochloride nasal spray, was given the go-ahead by the U.S. Food and Drug Administration for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older.

Weekly Mass Torts Bulletin 2023-May-29

The U.S. District Judge presiding over all Combat Arms Earplug complaints filed in federal courts nationwide has ordered the CEO of 3M Company to attend settlement negotiations aimed at settling hundreds of thousands of claims of hearing impairment since negotiations have reached a "critical juncture."

Weekly Mass Torts Bulletin 2023-May-22

Hundreds of plaintiffs have requested the federal court to reinstate their Zostavax shingles lawsuits which were earlier dismissed by the judge due to lack of evidence.

Weekly Mass Torts Bulletin 2023-May-15

Ten companies that combined produce and market roughly 6,500 flavored e-liquid and e-cigarette products were given marketing denial orders by the U.S. Food and Drug Administration (FDA).

Weekly Mass Torts Bulletin 2023-May-8

According to recently disclosed data, the number of drug overdose deaths containing the synthetic opioid fentanyl surged by 279% in the United States between 2016 and 2021.

Weekly Mass Torts Bulletin 2023-April-17

Lawyers for cancer patients stated in a court filing that Johnson & Johnson's second effort to settle talc cases through bankruptcy should be rejected as an unprecedented scam intended to deny plaintiffs proper recompense.

Weekly Mass Torts Bulletin 2023-April-10

The FDA stated that makers of opioid analgesics supplied in outpatient settings must make prepaid mail-back envelopes accessible to outpatient pharmacies and other dispensers as an alternative opioid analgesic disposal option for patients.